New Free-Breathing MRI could make liver scans easier for kids
NCT ID NCT04591106
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested new MRI and MRE techniques that let children breathe normally during scans, instead of holding their breath. The goal was to measure liver fat and stiffness more comfortably and accurately in kids with fatty liver disease. 135 children aged 6-17 took part, and the new method was compared to standard breath-hold scans and liver biopsies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
135 people
The number who actually took part.
- Started
-
Feb 2021
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Study 1 (Aim 1 and Aim 2): 50 healthy subjects 6-17 years old, 50 subjects with NAFLD 6-17 years old; Study 2 (Aim 3): 60 subjects with Liver Disease and Fibrosis 1 month-40 years old; Study 3 (Aim 4): Study 3 (Aim 4): 15 Pairs of Healthy Infants (1 week-6 months old) and their Mothers. 15 Pairs of Infants (1 week-6 months old) born to Mothers with Gestational Diabetes and their Mothers.
- Ages
-
1 week to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion and Exclusion Criteria Study 1 (Aim 1 and Aim 2): Inclusion criteria for the NAFLD cohort: * 6-17 years of age * BMI \>85th percentile * diagnosed or clinically suspected to have NAFLD (NAFLD or suspected NAFLD is defined as serum alanine transaminase concentration \>30 IU/L in the appropriate clinical setting) * ability to follow instructions and perform short breath holds Inclusion criteria for the healthy cohort: * 6-17 years of age * body mass index \<85th percentile * ability to follow instructions and perform short breath holds Exclusion criteria for both cohorts: * known liver disease (except for NAFLD/NASH for the NAFLD cohort) * congenital malformation * inborn error of metabolism * contraindications to MRI * inability to perform breath-holding Study 2 (Aim 3): Inclusion criteria: * children and adults 1 month-40 years of age * liver disease and suspected or confirmed fibrosis * clinically ordered liver biopsy * Liver diseases include NAFLD/NASH, viral/medication induced hepatitis, autoimmune sclerosing cholangitis, intestinal failure associated liver disease, idiopathic hepatitis, Wilson's disease, hemosiderosis, liver rejection, and metabolic/genetic disorders * A liver biopsy must be planned/anticipated, performed, or scheduled to be performed within ±6 months of the MRI/MRE for this study Exclusion Criteria: * contra-indications to MRI/MRE * inability to perform breath-holding Study 3 (Aim 4): Inclusion criteria for the cohort of infants at risk for future obesity and NAFLD: * 1 week-6 months of age * greater than or equal to 35 weeks gestational age * born to a mother with gestational diabetes and whose pre-pregnancy body mass index \>=25 kg/m2 * mother must provide consent to participate in the study Inclusion criteria for the healthy cohort: * 1 week-6 months of age * greater than or equal to 35 weeks gestational age * appropriate for gestational age birth weight * born to a mother with a pre-pregnancy body mass index \<25 kg/m2 and without any major co-morbid conditions (gestational diabetes, pregnancy-induced hypertension, etc.) * admitted to the newborn nursery after birth * mother must provide consent to participate in the study Exclusion criteria for both cohorts: * known liver disease and/or infection, major congenital anomalies, inborn error of metabolism * any contraindications for an MRI exam
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Autoimmune sclerosing cholangitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCLA Medical Center
Los Angeles, California, 90095, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Underactive thyroid may worsen liver scarring in fatty liver disease
- Sound waves may replace the needle in liver scarring tests
- Can a new ultrasound device spot liver damage without a biopsy?
- Can talk therapy and mindfulness shrink a fatty liver?
- Can tailoring bypass length improve weight loss surgery results?
- Can a Dual-Drug approach tackle fatty liver disease and diabetes together?